Mankind Pharma Limited (NSE:MANKIND)
India · Delayed Price · Currency is INR 2,443.70
+37.20 (1.55%)
Oct 29, 2025, 3:30 PM IST
Mankind Pharma Revenue
Mankind Pharma had revenue of 35.70B INR in the quarter ending June 30, 2025, with 23.40% growth. This brings the company's revenue in the last twelve months to 129.10B, up 21.22% year-over-year. In the fiscal year ending March 31, 2025, Mankind Pharma had annual revenue of 122.07B with 18.98% growth.
Revenue (ttm)
129.10B
Revenue Growth
+21.22%
P/S Ratio
7.81
Revenue / Employee
4.79M
Employees
26,978
Market Cap
1.01T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 122.07B | 19.47B | 18.98% |
| Mar 31, 2024 | 102.60B | 15.11B | 17.27% |
| Mar 31, 2023 | 87.49B | 9.68B | 12.44% |
| Mar 31, 2022 | 77.82B | 15.67B | 25.22% |
| Mar 31, 2021 | 62.14B | 3.43B | 5.83% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 537.77B |
| Aurobindo Pharma | 320.25B |
| Cipla | 274.80B |
| Zydus Lifesciences | 236.08B |
| Apollo Hospitals Enterprise | 225.51B |
| Biocon | 157.71B |
| Glenmark Pharmaceuticals | 134.56B |
| Alkem Laboratories | 133.04B |